Med Rx.

Ivosidenib + Oxytocin

Major 6 published sources

This interaction is documented in this data source.

Ivosidenib: Checked as Ivosidenib
Oxytocin: Checked as Oxytocin

What is documented

Synergy
Major

What happens

Ivosidenib can cause prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.

What to do

Coadministration of ivosidenib with other drugs that can prolong the QT interval should generally be avoided. Otherwise, close monitoring of electrocardiograms and electrolytes is recommended. If QT prolongation occurs during treatment, withhold and/or reduce dose in accordance with the product labeling. Ivosidenib should be permanently discontinued in patients who develop QT prolongation with signs or symptoms of life-threatening arrhythmia.
6 sources
1. "Product Information. Tibsovo (ivosidenib)." Agios Pharmaceuticals, Cambridge, MA.
2. "Product Information. Tibsovo (ivosidenib)." Agios Pharmaceuticals, Cambridge, MA.
3. "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.
4. Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):
5. Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7
6. "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.

Keep checking